Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody[S]

Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody[S]

Lilly PCSK9 antibody LY3015014 (LY) is a monoclonal antibody (mAb) that neutralizes proprotein convertase subtilisin-kexin type 9 (PCSK9). LY decreases LDL cholesterol in monkeys and, unlike other PCSK9 mAbs, does not cause an accumulation of intact PCSK9 in serum. Comparing the epitope of LY with o...

Full description

Bibliographic Details
Main Authors:	Krista M. Schroeder, Thomas P. Beyer, Ryan J. Hansen, Bomie Han, Richard T. Pickard, Victor J. Wroblewski, Mark C. Kowala, Patrick I. Eacho
Format:	Article
Language:	English
Published:	Elsevier 2015-11-01
Series:	Journal of Lipid Research
Subjects:	proprotein convertase subtilisin-kexin type 9 pharmacology pharmacokinetics low density lipoprotein/metabolism drug therapy dyslipidemias
Online Access:	http://www.sciencedirect.com/science/article/pii/S002222752035481X

Similar Items

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE[S]
by: Brandon Ason, et al.
Published: (2014-11-01)

Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
by: Bruce A. Warden, PharmD, et al.
Published: (2020-03-01)

Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice
by: Yi Luo, et al.
Published: (2009-08-01)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
by: Dennis T. Ko, et al.
Published: (2018-11-01)

Functional analysis of sites within PCSK9 responsible for hypercholesterolemias⃞
by: Shilpa Pandit, et al.
Published: (2008-06-01)

Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors
by: Øystein L. Holla, et al.
Published: (2011-10-01)

ASSOCIATION OF POLYMORPHISM IN PCSK9 GENE WITH LIPID PR OFILE IN RUSSIAN POPULATION
by: K. S. Astrakova, et al.
Published: (2016-06-01)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01)

PCSK9 gene participates in the development of primary dyslipidemias
by: Matías-Pérez D, et al.
Published: (2021-07-01)

PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults
by: Matthew T. Mefford, et al.
Published: (2019-11-01)

High-Throughput Screening Identifies MicroRNAs Regulating Human PCSK9 and Hepatic Low-Density Lipoprotein Receptor Expression
by: Coen van Solingen, et al.
Published: (2021-07-01)

Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia
by: R. Huijgen, et al.
Published: (2012-05-01)

The PCSK9 decade
by: Gilles Lambert, et al.
Published: (2012-12-01)

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”
by: Payal Kohli, et al.
Published: (2016-05-01)

Physical activity to reduce PCSK9 levels
by: Amedeo Tirandi, et al.
Published: (2022-08-01)

Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population
by: Ilaria Guella, et al.
Published: (2010-11-01)

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the treatment of dyslipidemia
by: A. A. Shikaleva, et al.
Published: (2021-01-01)

PCSK9 Biology and Its Role in Atherothrombosis
by: Cristina Barale, et al.
Published: (2021-05-01)

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
by: Qianyun Guo, et al.
Published: (2020-09-01)

The predictive utility of circulating PCSK9 levels on diabetes mellitus
by: Jia Peng, et al.
Published: (2021-02-01)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
by: Michael D. Shapiro, et al.
Published: (2019-02-01)

Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor
by: Sarah J. Duellman, et al.
Published: (2017-08-01)

Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction
by: A. D. Gimadeeva, et al.
Published: (2020-03-01)

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]
by: Frederick J. Raal, et al.
Published: (2016-06-01)

Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells[S]
by: Aiqin Cao, et al.
Published: (2011-03-01)

The association of the PCSK9 rs562556 polymorphism with serum lipids level: a meta-analysis
by: Junlan Chuan, et al.
Published: (2019-04-01)

Editorial: PCSK9: Importance in Physiology and Pathophysiology
by: Rainer Schulz, et al.
Published: (2021-07-01)

Evolocumab, a PCSK9‐Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia
by: Thorsten M. Leucker, et al.
Published: (2020-07-01)

PCSK9 inhibitors in clinical practice: Novel directions and new experiences
by: Loukianos S. Rallidis, et al.
Published: (2020-07-01)

Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia[S]
by: Victor Sokolov, et al.
Published: (2019-09-01)

Use of Low‐Density Lipoprotein–Lowering Therapies Before and After PCSK9 Inhibitor Initiation
by: Jennifer A. Rymer, et al.
Published: (2020-05-01)

Efficacy of Evolocumab in Patients with Hypercholesterolemia
by: Xuan Jin, et al.
Published: (2020-12-01)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
by: Aureli Luquero, et al.
Published: (2021-03-01)

The rs508487, rs236911, and rs236918 Genetic Variants of the Proprotein Convertase Subtilisin–Kexin Type 7 (<i>PCSK7</i>) Gene Are Associated with Acute Coronary Syndrome and with Plasma Concentrations of HDL-Cholesterol and Triglycerides
by: Gilberto Vargas-Alarcón, et al.
Published: (2021-06-01)

Prognostic Impacts of LL-37 in Relation to Lipid Profiles of Patients with Myocardial Infarction: A Prospective Cohort Study
by: Runzhen Chen, et al.
Published: (2022-10-01)

Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population
by: Wen Guo, et al.
Published: (2018-01-01)

What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis
by: Chengfeng Qiu, et al.
Published: (2017-06-01)

Association and differences in genetic polymorphisms in PCSK9 gene in subjects with lacunar infarction in the Han and Uygur populations of Xinjiang Uygur Autonomous Region of China
by: Deng-feng Han, et al.
Published: (2017-01-01)

Pretreatment With PCSK9 Inhibitor Protects the Brain Against Cardiac Ischemia/Reperfusion Injury Through a Reduction of Neuronal Inflammation and Amyloid Beta Aggregation
by: Nattayaporn Apaijai, et al.
Published: (2019-01-01)

In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction
by: Bowen Lou, et al.
Published: (2022-10-01)